




## Annex to the Press Release

### Evolution diagnostic trade sales (in thousands EUR)



**HPV:** Human papillomaviruses are a group of over 100 types of viruses of which 30 are sexually transmissible. Specific high-risk HPVs are the major cause of cervical cancer, the second most common cancer in women.

**HLA:** Human leukocyte antigen: a set of proteins expressed on the surface of cells that allow the body to discriminate between self and non-self. Before transplantation, the process of tissue typing determines the presence and absence of these proteins to ensure that the organ donor and recipient are compatible.

**LiPA** or line probe assay is a DNA-based, multiparameter (ie, able to measure many items with one test) detection and identification technology that provides high value-added diagnostic information to physicians throughout therapy, enabling them to optimize the therapeutic regimen of patients.

**LIA<sup>®</sup>** or line immunoassay tests are advanced confirmatory tests allowing rapid and simultaneous detection and differentiation of multiple disease parameters, such as antibodies, in human serum or plasma samples.



**INNOGENETICS**  
BIOTECHNOLOGY FOR HEALTHCARE

**Unaudited Consolidated Balance Sheet  
as at September 2008 compared to December 2007**

*In thousands EUR  
According to IFRS*

	<b>30 September 2008</b>	<b>31 December 2007</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	13 012	23 478
Accounts receivable	17 438	19 060
Inventories	8 908	10 210
<u>Other accounts receivable</u>	<u>1 989</u>	<u>1 621</u>
<b>Total current assets</b>	<b>41 347</b>	<b>54 369</b>
<b>Non current assets</b>		
Intangible assets	20 651	30 597
Property, plant and equipment	15 161	19 600
<u>Accounts receivable more than one year</u>	<u>372</u>	<u>359</u>
<b>Total non current assets</b>	<b>36 183</b>	<b>50 556</b>
<b>TOTAL ASSETS</b>	<b><u>77 530</u></b>	<b><u>104 925</u></b>
<b>LIABILITIES &amp; SHAREHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Current instalments of long-term obligations	32 595	9 932
Trade accounts payable	9 950	8 798
Other current liabilities	20 315	14 579
<u>Current tax liabilities</u>	<u>225</u>	<u>187</u>
<b>Total current liabilities</b>	<b>63 084</b>	<b>33 496</b>
<b>Non current liabilities</b>		
Long-term obligations	9 038	41 039
Provisions	1 008	762
<u>Other non current liabilities</u>	<u>1 197</u>	<u>1 677</u>
<b>Total non current liabilities</b>	<b>11 243</b>	<b>43 478</b>
<b>Shareholders' equity</b>		
Share capital	19 398	19 398
Issuance premium	154 994	163 070
Reserves	(1 285)	(1 501)
<u>Retained earnings</u>	<u>(169 905)</u>	<u>(153 016)</u>
<b>Total shareholders' equity</b>	<b>3 202</b>	<b>27 951</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b><u>77 530</u></b>	<b><u>104 925</u></b>



**INNOGENETICS**  
BIOTECHNOLOGY FOR HEALTHCARE

## Unaudited Consolidated Income Statement for the nine months ended September 30

*In thousands EUR  
According to IFRS*

	9 months ended Sep. 2008	9 months ended Sep. 2007	3 months ended Sep. 2008	3 months ended Sep. 2007
<b>CONTINUING OPERATIONS</b>				
Product sales	38 569	37 699	11 017	12 217
Royalties	3 183	2 940	1 267	1 045
<u>License fees</u>	<u>1 324</u>	<u>153</u>	<u>166</u>	<u>131</u>
<b>Revenues</b>	<b>43 076</b>	<b>40 792</b>	<b>12 450</b>	<b>13 393</b>
<u>Cost of sales</u>	<u>(18 569)</u>	<u>(17 416)</u>	<u>(5 806)</u>	<u>(5 388)</u>
<b>Gross profit/(loss)</b>	<b>24 507</b>	<b>23 376</b>	<b>6 644</b>	<b>8 005</b>
Grants received for research & development	477	1 027	229	475
Research & development contract income	1 583	1 532	464	423
<u>Research &amp; development expenses</u>	<u>(14 281)</u>	<u>(20 105)</u>	<u>(3 876)</u>	<u>(6 144)</u>
<b>Research &amp; development</b>	<b>(12 221)</b>	<b>(17 546)</b>	<b>(3 183)</b>	<b>(5 246)</b>
Marketing & sales expenses	(10 861)	(11 517)	(3 551)	(3 598)
<u>Administration expenses</u>	<u>(6 341)</u>	<u>(3 459)</u>	<u>(1 345)</u>	<u>(1 276)</u>
<b>Operating expenses</b>	<b>(17 202)</b>	<b>(14 976)</b>	<b>(4 896)</b>	<b>(4 874)</b>
<b>Operating profit/(loss) before restructuring, impairment losses and other non-recurring items</b>	<b>(4 916)</b>	<b>(9 146)</b>	<b>(1 435)</b>	<b>(2 115)</b>
<b>Restructuring, impairment losses, &amp; other non-recurring expenses</b>	<b>(18 130)</b>	<b>0</b>	<b>(10 098)</b>	<b>0</b>
<b>Operating profit/(loss) (EBIT)</b>	<b>(23 046)</b>	<b>(9 146)</b>	<b>(11 533)</b>	<b>(2 115)</b>
Interest expenses	(2 714)	(2 505)	(928)	(1 022)
Interest income	476	811	101	257
<u>Investment income and other</u>	<u>8 628</u>	<u>179</u>	<u>3 457</u>	<u>(121)</u>
<b>Other income/(expenses)</b>	<b>6 390</b>	<b>(1 515)</b>	<b>2 630</b>	<b>(886)</b>
<b>Profit/(loss) before taxes</b>	<b>(16 656)</b>	<b>(10 661)</b>	<b>(8 903)</b>	<b>(3 001)</b>
Income taxes – (payable)/adjustment	(233)	(122)	28	12
<b>Net profit/(loss)</b>	<b><u>(16 889)</u></b>	<b><u>(10 783)</u></b>	<b><u>(8 875)</u></b>	<b><u>(2 989)</u></b>
<b>Operating profit/(loss) before depreciation and amortization (EBITDA)</b>	<b><u>(6 017)</u></b>	<b><u>(2 159)</u></b>	<b><u>(3 817)</u></b>	<b><u>316</u></b>



**INNOGENETICS**  
BIOTECHNOLOGY FOR HEALTHCARE

**Unaudited Consolidated Income Statement  
for the nine months ended September 30  
(continued)**

*In EUR per share (except share amounts)  
According to IFRS*

	<b>9 months ended</b>		<b>3 months ended</b>	
	<b>Sep. 2008</b>	<b>Sep. 2007</b>	<b>Sep. 2008</b>	<b>Sep. 2007</b>
<b>EPS from continuing operations (basic/diluted)</b>	<b>(0.55)</b>	<b>(0.35)</b>	<b>(0.28)</b>	<b>(0.10)</b>
Shares used in computing per share amount (basic)	30 878 920	30 878 920	30 878 920	30 878 920
Shares used in computing per share amount (diluted)	30 878 920	30 878 920	30 878 920	30 878 920



## Unaudited Consolidated Statement of Shareholders' Equity

In thousands EUR (except share amounts)  
According to IFRS

### Movements during the nine months of 2007

	Equity attributable to the equity holders of the Company					
	Number of shares issued	Share capital	Issuance premium	Retained earnings profit/(loss)	Accumulated currency translation and fair value adjustments	TOTAL shareholders' equity
<b>Total as per December 31, 2006</b>	<b>30 878 920</b>	<b>19 398</b>	<b>157 419</b>	<b>(135 639)</b>	<b>(856)</b>	<b>40 322</b>
Currency translation adjustment					(442)	(442)
Net profit/(loss)				(10 783)		(10 783)
Recognition of share-based payment			131			131
Recognition of equity component of convertible bond			5 521			5 521
<b>Total as per September 30, 2007</b>	<b>30 878 920</b>	<b>19 398</b>	<b>163 071</b>	<b>(146 422)</b>	<b>(1 298)</b>	<b>34 749</b>

### Movements during the first nine months of 2008

<b>Total as per December 31, 2007</b>	<b>30 878 920</b>	<b>19 398</b>	<b>163 070</b>	<b>(153 016)</b>	<b>(1 501)</b>	<b>27 951</b>
Currency translation adjustment					217	217
Net profit/(loss)				(16 889)		(16 889)
Recognition of share-based payment			29			29
Recognition of equity component of Convertible Bond			(8 105)			(8 105)
<b>Total as per September 30, 2008</b>	<b>30 878 920</b>	<b>19 398</b>	<b>154 994</b>	<b>(169 905)</b>	<b>(1 284)</b>	<b>3 203</b>



**INNOGENETICS**  
BIOTECHNOLOGY FOR HEALTHCARE

**Unaudited Consolidated Statement of Cash Flows (Indirect method)  
for the nine months ended September 30**

*In thousands EUR  
According to IFRS*

	9 months ended		3 months ended	
	Sep. 2008	Sep. 2007	Sep. 2008	Sep. 2007
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>				
<b>Net profit/(loss)</b>	<b>(16 889)</b>	<b>(10 783)</b>	<b>(8 875)</b>	<b>(2 989)</b>
Depreciation, amortization and impairment results	17 029	6 987	7 716	2 431
Increase/(decrease) in provisions	246	(3 628)	4	(1 072)
Share-based payment	29	132	3	21
Gain on disposal of fixed assets	(177)	(12)	(53)	(5)
Loss on disposal of fixed assets	44	451	0	325
Interest paid	2 714	2 505	928	995
Interest received	(451)	(767)	(100)	(256)
(Increase)/decrease in accounts receivable	1 240	40	729	(1 015)
(Increase)/decrease in inventories	1 302	(2 283)	1 307	(281)
Increase/(decrease) in accounts payable	1 152	(984)	2 658	(1 587)
Increase/(decrease) in accruals and other liabilities	(4 633)	(3 336)	(3 755)	(822)
Increase/(decrease) in current tax liabilities	38	(95)	(53)	62
Increase/(decrease) in non current liabilities	(479)	(130)	(37)	86
<b>Total adjustments</b>	<b>18 054</b>	<b>(1 120)</b>	<b>9 347</b>	<b>(1 117)</b>
<b>Net cash provided by/(used in) operating activities</b>	<b>1 165</b>	<b>(11 903)</b>	<b>472</b>	<b>(4 107)</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>				
Purchase of property, plant and equipment	(1 568)	(3 099)	49	(1 107)
Purchase of intangible assets	(942)	(1 334)	(453)	(89)
<b>Net cash provided by/(used in) investing activities</b>	<b>(2 510)</b>	<b>(4 433)</b>	<b>(404)</b>	<b>(1 196)</b>



**INNOGENETICS**  
BIOTECHNOLOGY FOR HEALTHCARE

**Unaudited Consolidated Statement of Cash Flows  
for the nine months ended September 30  
(continued)**

*In thousands EUR  
According to IFRS*

	9 months ended		3 months ended	
	Sep. 2008	Sep. 2007	Sep. 2008	Sep. 2007
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>				
Payments on long-term obligations	(7 950)	(5 434)	(767)	(1 006)
Proceeds from long-term obligations	1 811	2 455	768	1 016
Payments on notes payable to bank	0	(1 913)	0	(478)
Currency translation adjustment	217	(442)	477	(311)
Repurchase of convertible bond	(3 199)	0	(3 199)	0
Transaction cost	0	30 664	0	0
<b>Net cash provided by/(used in) financing activities</b>	<b>(9 121)</b>	<b>25 330</b>	<b>(2 721)</b>	<b>(779)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(10 466)</b>	<b>8 994</b>	<b>(2 653)</b>	<b>(6 082)</b>
Cash and cash equivalents at beginning of period	23 478	22 349	15 665	37 425
<b>Cash and cash equivalents at end of period</b>	<b>13 012</b>	<b>31 343</b>	<b>13 012</b>	<b>31 343</b>



**INNOGENETICS**  
BIOTECHNOLOGY FOR HEALTHCARE

**Unaudited Segment Information  
for the nine months ending September 30**

*According to IFRS  
In thousands EUR*

	Diagnostics		Therapeutics		Total	
	Sep. 2008	Sep. 2007	Sep. 2008	Sep. 2007	Sep. 2008	Sep. 2007
<b>CONTINUING OPERATIONS</b>						
<b>Revenues</b>	<b>40 844</b>	<b>38 488</b>	<b>2 232</b>	<b>2 304</b>	<b>43 076</b>	<b>40 792</b>
<b>Gross profit</b>	<b>23 581</b>	<b>23 102</b>	<b>926</b>	<b>274</b>	<b>24 507</b>	<b>23 376</b>
R&D income	321	799	1 739	1 760	2 060	2 559
R&D expenses	<u>(8 553)</u>	<u>(10 885)</u>	<u>(5 728)</u>	<u>(9 220)</u>	<u>(14 281)</u>	<u>(20 105)</u>
<b>Net R&amp;D expenses</b>	<b>(8 232)</b>	<b>(10 086)</b>	<b>(3 989)</b>	<b>(7 460)</b>	<b>(12 221)</b>	<b>(17 546)</b>
<b>Operating expenses</b>	<b>(15 140)</b>	<b>(12 359)</b>	<b>(2 062)</b>	<b>(2 617)</b>	<b>(17 202)</b>	<b>(14 976)</b>
<b>Operating profit/(loss) before restructuring, impairment losses and other non-recurring items</b>	<b>209</b>	<b>657</b>	<b>(5 125)</b>	<b>(9 803)</b>	<b>(4 916)</b>	<b>(9 146)</b>
<b>Restructuring, impairment losses and other non-recurring expenses</b>	<b>(10 202)</b>	<b>0</b>	<b>(7 928)</b>	<b>0</b>	<b>(18 130)</b>	<b>0</b>
Operating profit/(loss) before depreciation and amortization (EBITDA)	551	5 704	(6 568)	(7 863)	(6 017)	(2 159)
<b>Operating profit/(loss) (EBIT)</b>	<b>(9 993)</b>	<b>657</b>	<b>(13 053)</b>	<b>(9 803)</b>	<b>(23 046)</b>	<b>(9 146)</b>